Clinical trial
A Phase I, Randomized, Single-blind, Placebo-controlled, 2-Part Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD4916 Following Single- and Multiple-ascending-dose Administration to Healthy Adult Volunteers (Including Japanese and Chinese Healthy Volunteers)
NCT06951880 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Randomized, Single-blind, Placebo-controlled, 2-Part Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD4916 Following Single- and Multiple-ascending-dose Administration to Healthy Adult Volunteers (Including Japanese and Chinese Healthy Volunteers)
- Lead sponsor
- AstraZeneca
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- July 23, 2026
- Completion date
- December 20, 2027
- Enrollment
- 160 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
healthy participants